This post was originally commissioned for PharmaPhorum in August 2018
With studies showing potential for SGLT2 inhibitors in heart failure, our study of HCP online conversations reveals cardiologists are still cautious
Earlier this year, Boehringer Ingelheim and Lilly announced an expansion to the clinical trial program for Jardiance (empagliflozin) in chronic heart failure. The SGLT2 inhibitor drug, which is used to treat patients with type 2 diabetes, was previously found to have favorable results in heart failure among diabetes patients, sparking excitement about possible new indications for the class outside of diabetes.
AstraZeneca had already been quick to consider the class-wide impact of the cardiovascular benefits of SGLT2 inhibitors, launching a study of type 2 diabetes patients on various SGLT2 inhibitors including its own product, Farxiga (dapagliflozin). In March this year, the company announced results supporting the association of CV benefits with Farxiga.
But Boehringer’s trial goes beyond improved CV outcomes for diabetes patients to consider its product’s role for heart failure patients who do not have diabetes. Heart failure is estimated to affect 26 million people worldwide, and the indication could open up new opportunities for the product’s use among a new patient group.
All of which means manufacturers of SGLT2 inhibitors are faced with a potential new group of customers – cardiologists treating heart failure – who may not yet be familiar with their products.
— Alfonso Valle (@ValleAlfonso) May 28, 2018
We took a look at the collective intelligence of healthcare professionals (HCPs) in the United States to discover how they are anticipating the use of SGLT2 inhibitors in heart failure. Using CREATION Pinpoint, the HCP insights platform, we studied the online conversations of HCPs in the US from January through July 2018, talking about heart failure and SGLT2 inhibitors.
Cardiologists talk about heart failure
It’s no surprise to learn that cardiologists, more than any other specialty, lead the online HCP conversation about heart failure. Cardiologists not only contributed the largest voice – over 3,000 posts – to the physician conversation about heart failure; they discussed heart failure almost as much as all other physician specialties combined (who mentioned heart failure a little over 3,800 times).
Cardiologists start discussing SGLT2 inhibitors
Our analysis of US HCP online conversations about SGLT2 inhibitors in relation to heart failure shows that a wide range of HCPs are sharing the latest data and are excited by the positive results. Cardiologists, however, appear to be slow to celebrate the role of the class in treating heart failure.
During the period of analysis, cardiologists only discussed SGLT2 inhibitors in relation to heart failure immediately after news of study results, when there was a significant spike in conversation across all role types.
When study data was discussed, it seems that some of the cardiologists’ interest was sparked by HCP peers in other role types. After initial news about study data, cardiologists’ posts about SGLT2 inhibitors in heart failure tailed off rapidly.
That is not to say that there were no cardiologists getting excited about the new data, though. US physicians reacted when Alfonso Valle, a cardiologist in Spain, shared a slide presenting the use of SGLT2 inhibitors for the treatment of heart failure patients without type 2 diabetes, calling it a “paradigm shift”. As well as engaging US physicians, his tweet was widely shared by other cardiologists in Spain.
Cardiologists are positive but cautious
HCPs familiar with SGLT2 inhibitors for the treatment of type 2 diabetes are interested to find out what cardiologists think about the class for heart failure. In fact, in the context of our analysis, non-cardiologist HCPs mentioned cardiologists far more than cardiologists did, and they talked about them mostly in the context of heart failure.
New York based Nephrologist Kenar Jhaveri asked what cardiologists and nephrologists thought about the use of the class in CHF, sparking responses from several nephrologists but no cardiologists.
Overall, those cardiologists who mentioned SGLT2 inhibitors for heart failure were positive, but there was notable caution among their comments too.
— Kenar Jhaveri (@kdjhaveri) February 14, 2018
What’s holding cardiologists back?
“My enthusiasm is… submaximal”, tweeted US cardiologist J. Brian Byrd, stating that he feels more data is needed.
Others were concerned that there was uncertainty about the mechanism.
Cost was also a concern raised by cautious cardiologists like Hashim Khan. “All well and good but what about cost?” he tweeted.
Brian Bird was also cautious about adverse effects, citing the issue of limb amputation and sharing concerns that this may be a class effect.
We will have to see how the data from big studies RCTs, post-marketing analyses look.
So, for dapagliflozin, we await a placebo-controlled trial showing improved CV outcomes in diabetes; canagliflozin has a boxed warning re: amputations. Accurate?
My enthusiasm is… submaximal
— J. Brian Byrd Lab (@thebyrdlab) July 3, 2018
A call for cardiologists to step up
There were some cardiologists who called for their peers to step up and take an interest in SGLT2 inhibitors. In a discussion about cardiologists prescribing diabetes drugs, Harvard cardiologist Jordan Strom called for cardiologists to become familiar with diabetes medication.
Cardiologist Hani Jneid joined an international discussion about whether cardiologists should become diabetologists too, concluding that they should at least be familiar with newer agents that not only control diabetes but also protect against cardiovascular events.
What next for SGLT2 in cardiology?
From this brief research, we see that:
- HCPs, including cardiologists, are excited by the possibility of using SGLT2i in heart failure.
- However some cardiologists are cautious, they want more data and may not trust SGLT2 inhibitors yet
- Other HCPs want cardiologists to be leaders in this space, feeling that they should use these drugs in practice and share their knowledge with others
Actually, the study shows that changes in plasma volume may be the best marker we can measure of target (SGLT2) engagement-there is no direct causal link with #CVD and no one (yet) has mechanistic proof that explains the cardioprotective actions of SGLT2 inhibitors #diabetes https://t.co/cTmPxooVVx
— Daniel J Drucker (@DanielJDrucker) May 30, 2018
For cardiologists to take a lead, it appears that reassurance is needed and perhaps collaboration between roles, with cardiologists learning from diabetologists who are more experienced in the use of the class.
Data to inform this article was taken from online HCP conversations posted from January through July 2018 collected using CREATION Pinpoint®